




SAPIENZA
Università di Roma
Facoltà di Farmacia e Medicina

Ph.D. in MORPHOGENESIS AND TISSUE ENGINEERING
XXXII Ciclo
A.A. 2018/2019



**Evaluation of the histopathological modifications
induced by the positioning of
autologous platelets-rich plasma
vs. biosynthetic, absorbable mesh
as reinforcement of the cruroplasty:
a pilot study on an animal model**

Cristian Eugeniu Boru, MD, Ph.D. Student

Tutor
Prof. Gianfranco Silecchia

Coordinator
Prof. Antonio Musarò

Cristian Eugeniu Boru

Pag 2

Evaluation of the histopathological modifications induced by the positioning of autologous platelet-rich plasma vs. biosynthetic, absorbable mesh as reinforcement of the cruroplasty: a pilot study on an animal model

Dr. Cristian Eugeniu Boru MD, PhD student

PhD candidate in Morphogenesis & Tissue Engineering
Department of Anatomical Sciences, Histology, Forensics and of the Locomotor Apparatus (SAIMLAL)
Histology and Medical Embryology Section
University La Sapienza of Rome

Prof. Gianfranco Silecchia, MD, PhD

Full Professor of Surgery

Director of UOC & Bariatric Centre of Excellence-IFSO EC
Department of Medico-Surgical Sciences and Biotechnologies
UOC General Surgery & Bariatric Centre of Excellence-IFSO EC
University La Sapienza of Rome, Polo Integrato AUSL LT-ICOT
gianfranco.silecchia@uniroma1.it

Prof. Dr. Nicolae Manolescu, PhD, Professor Emeritus

Member of Romanian Academy
Member of The French National Academy of Medicine
Department of Morphopathology and Comparative Oncology
Faculty of Veterinary Medicine
Spiru Haret University, Bucharest, Romania
manolescunicolae@yahoo.com

Prof. Catalin Copaescu, MD, PhD

Associated Professor of Surgery
Head of Minimal Invasive and Metabolic Surgery Dept.,
Director of the Bariatric & Metabolic Surgery Program
Bariatric Centre of Excellence IFSO EAC-EC
International SRC Centre of Excellence

Cristian Eugeniu Boru

Ponderas Hospital, Bucharest, Romania
catalin.copaescu@ponderas-ah.ro

Prof. Dan Ulmeanu, MD, PhD,
Associated Professor of Surgery
Faculty of Medicine, Titu Maiorescu University, Bucharest
Head of General and Thoracic Surgery Department
Regina Maria Baneasa Hospital, Bucharest, Romania
d_ulmeanu@yahoo.com

INDEX

1. Index	pag. 5
2. Summary	pag. 7
3. Introduction	pag. 9
4. Aims of the study	pag. 17
5. Materials and methods	pag. 19
5.1 type of study	pag. 19
5.2 PRP preparation	pag. 20
5.3 surgical procedures	pag. 21
5.4 histopathological examination	pag. 25
5.5 statistical considerations	pag. 29
6. Results	pag. 31
6.1 histopathological results	pag. 31
6.2 statistical analysis results	pag. 34
7. Discussions	pag. 37
8. Conclusions	pag. 47
9. Figures	pag. 49
10. Tables	pag. 71
11. List of publications	pag. 77
12. References	pag. 81

Cristian Eugeniu Boru

Pag 6

1. SUMMARY

Introduction: Symptomatic hiatal hernia's (HH) incidence, associated with gastroesophageal reflux disease (GERD), ranges between 10-20% in the general population. Laparoscopic suture of the diaphragmatic crura (posterior cruroplasty PC) during the HH's surgical treatment determines good long-term results in the majority of cases, without cancelling the risks of recurrences or surgical revisions. Based on anatomical, physiological, morphological and evolution of certain diseases, the use of porcine model became one of the most important research fields, including laparoscopic implant of prosthetic materials. Cruroplasty's reinforcement is widely used in large hiatal defects for recurrences' reduction with no consensus on type or shape of mesh. The use of autologous platelet-rich plasma (PRP) concentrate, simple and cheap prepared, might be an alternative option. Aims: finding new solutions for the laparoscopic treatment of symptomatic HH, in particular comparing a biosynthetic, absorbable mesh, vs. autologous PRP in a porcine model, in order to determine local histopathological (HP) changes and complications. Rationale: the literature lacks on comparative studies on the use of PRP for the reinforcement of hiatal defects repair. Materials and methods: Prospective, randomized study on 12 pigs. The laparoscopic procedure consisted in creation of a hiatal defect, then sutured PC, reinforced with absorbable mesh (group A) or PRP positioning (group B). Blood withdrawal was made prior to surgery for autologous concentrate's preparation in group B. The animals survived the procedure and professional care was taken for the next 7 months. Second procedure was performed afterwards, consisting in euthanasia, laparoscopy, and laparotomy for specimen retrieval (whole hiatal area). HP examination was performed, evaluating 4 main components: proliferative fibroblast – fibrocyte – collagen neoformation; vascular; inflammatory; and dystrophic. A semiquantitative HP scoring of tissue reaction was elaborated. Expected Results: direct consequences on the public health for the

management of the HH/GERD, definition of the technical indications, avoiding costly materials loss. Results: animals survived 7 months of postoperative care, with normal growth and without complications related to the surgical procedures. There were no complications, local or general, in both groups, with more intense adherential process in group A at the gross examination. Complete resorption of both products was demonstrated on gross and HP examination. Both reinforcements determined inflammatory infiltrates predominantly mononuclear, with induced local collagen production and tissue neo-vascularization. Animals in the mesh group had increased mean chronic inflammation score (2.66 vs. 1.83, $p = 0.908$) compared to the PRP group. Vascular network did not differ between groups ($p = 0.3061$), although there was an increased trend toward mean collagen fibers in the mesh group (score 2.83 ± 0.4) compared to PRP (2.33 ± 0.81), $p=0.248$.

Conclusions: Our laparoscopic, animal model of hiatal hernia repair was reliable, feasible and reproducible. The comparative study of both materials, autologous and biosynthetic, did not show any specific complications, with no residual material found after 7 months. The mesh group showed a more important score of sclerotic collagenising process. PRP was shown to be an autologous source of pro-regenerative growth factors and chemokines suited to hiatal area wound healing, enhanced angiogenesis, myofibroblast recruitment and tissue ingrowth and less severe peritoneal adhesions. The novelty of the study and the histopathological results suggest the use of combined products, so autologous PRP could find a clinical application in the surgical treatment of the hiatal defects, as a promising co-adjuvant to local remodeling and healing in this animal model. Next studies should verify that the use of PRP could improve the crura's weakness.

Keywords: Hiatal hernia, platelets-rich plasma, biosynthetic absorbable mesh, laparoscopy, pigs.

2. INTRODUCTION

Hiatal hernia's (HH) prevalence is estimated up to 50% of the general population, while the incidence of the symptomatic HH, associated with gastroesophageal reflux disease (GERD) ranges between 10-20%. Symptomatic GERD represents the most prevalent gastrointestinal disturb in the USA, with a relevant risk of severe chronic esophagitis, Barrett esophagus and even esophageal adenocarcinoma development¹.

Laparoscopic treatment of symptomatic hiatal hernia is already established as first choice option, and laparoscopic Nissen fundoplication (LFN), associated with posterior cruroplasty (PC), represents the gold standard². The fundoplication remakes an insufficient lower esophageal sphincter (LES) using the gastric fundus, in order to create a barrier at the level of the gastroesophageal junction (GEJ)³, while reinforcement of the PC is advised in case of large hiatal defects and/or weakness of the crura⁴. Simple suture of the hiatus has been associated with good long-term results, but recurrences and increased rate of surgical revision may be seen even in high volume, specialized centers⁵. Reparation's susceptibility of disruption in patients with HH was demonstrated to be caused by the ultrastructural abnormalities at the muscular tissue of the crura and the outcome of the anti-reflux surgery could depend not only on the surgical technique, but also on the quality of the diaphragmatic crura⁶.

Reinforcement of the sutured PC in HH repair, in the presence of large hiatal defects and / or weakness of the diaphragmatic pillars, has gained worldwide interest due to the availability of new materials.

Mesh reinforcement has been proposed as a method of recurrence prevention by Frantzides⁷. The indication for mesh use is directly determined by the defect size and quality of the pillars. There is no consensus on the size, type, shape, and position of mesh on the hiatus (SAGES², EAES⁴). The concerns regarding permanent mesh use are determined by the risks of erosion into the esophagus

and other nearby vital organs, local infections, and technical difficulties, dysphagia, fibrosis, stenosis of the esophago-gastric junction, and complete transmural gastric migration^{8, 9}. The European Association of Endoscopic Surgeons (EAES) recommended in 2014 the use of mesh limited to large hiatal defect and weak crura⁴ while SAGES recognized the controversies on the use of mesh on the hiatus². A tailored surgical approach was suggested by different Authors^{10, 11}: simple suture of the crura, reinforced suture or tension-free reinforced suture; the choice should be made based on pre- or intraoperative measurement of Hiatal Surface Area. This area is determined by the two-dimensional expanse of the hiatal orifice, measuring the length of the crura in centimeters beginning at the crural commissure up to the edge where the *pars flaccida* begins and the circuit between the both crural lateral edges.

Mesh materials in hiatal hernia repair

There are 3 categories of mesh available on the market:

1. Biological scaffolds origin from porcine dermis or intestine, bovine dermis or pericardium or even human cadaveric dermis or *fascia lata*. It was suggested that biological, absorbable meshes might be used even in clean-contaminated or contaminated situations, due to a better clearance of the bacteria, whereas biosynthetic meshes are not indicated. In the same time bacterial colonization may lead to accelerated enzymatic degradation of the mesh, with less long-term satisfactory results. Oelschlager reported use of biologic mesh for laparoscopic repair of large, complicated hiatal hernias that appeared safe, with no major complications related to the mesh, and overall satisfaction with the operation was very good¹².

Over these advantages, the costs of these prostheses are high, handling and fixation might be difficult, while the possibility of immunological reactions are also reasons of concern. There is insufficient data to establish the optimal use in different surgical procedures, as well as on the crura^{13, 14}.

2. Non-absorbable biosynthetic meshes raise major concerns about the long-term risk of mesh erosion. Popular use for repair of incisional hernias might advocate for their use in reinforced cruroplasty¹⁵, because they incorporate rapidly into host tissue and have lower recurrence rate^{7, 16}. On the other hand, anecdotal reports contra-indicated the use of these prostheses in the reinforcement of the HH's repair; permanent mesh might be associated with risks of organ resections at revisions for failed HH's surgery^{9, 17}. Specially designed, V-shaped, non-absorbable, covered mesh was specially created for use on the hiatal area¹⁶, with large-scale use, but recently it was withdrawn from the market for not-reported adverse effects¹⁸.

3. Absorbable biosynthetic scaffolds (on short and long-term) have different components like polyglycolic acid (PGA) in Dexon[®] (Covidien, Mansfield, MA); copolymer of glycolide and lactide in Vicryl[®] (Ethicon, Inc., Somerville, NJ); copolymer of polyglycolide: trimethylene carbonate in Gore[®] Bio-A[®] (W.L. Gore & Associates, Inc., Flagstaff, AZ); or different combinations, like macroporous multifilament absorbable biosynthetic mesh in Tigr Matrix[®] (Novus Scientific, Uppsala, Sweden). The use of biosynthetic meshes reduced the incidence of recurrences^{8, 19, 20}.

This type of mesh requires the presence of a substrate where fibrous tissue can be formed, so that the new structure remains after mesh absorption. Rapid absorption, like in case of Vicryl[®] or Dexon[®], determine weakening of the mechanical strength and make them not suitable for the use in hernia repairs that requires long-term support. Medium or long-term absorbable scaffolds like Gore[®] Bio-A[®], Tigr Matrix[®] and Phasix[™] Mesh (C.R. Bard, Inc./Davol Inc., Warwick, RI) are fully absorbable scaffolds due to hydrolysis and/or enzymatic reactions, providing long-term support (6-18 months), bacteria cleaning, with use in different abdominal wall defects²¹. There is a shortness of studies to establish the safety and effectiveness of absorbable mesh reinforcement in hiatal hernia repair; it was shown that the use of resorbable biosynthetic meshes in the prevention or treatment of abdominal wall defects in animal experiments with small defects in clean setting seems safe, with no

serious complications related to the device during short-term follow-up²². Although a certain degree of remodeling occurs, it remains completely unclear whether this can lead to strong fascial tissue of good quality in the long term.

Currently the only biosynthetic, absorbable mesh with CE mark for hiatal hernia use is Gore® Bio-A® Tissue Reinforcement since 2008, as well as Food and Drug Administration's (FDA, USA) approval for soft tissue reinforcement since 2017²³.

There is no clear experimental evidence currently available that can support the advantages of absorbable biosynthetic meshes over the use of biosynthetic non-absorbable or biological meshes in human settings, mostly due to lack of good data. More experimental studies were shown to be needed, using standardized models and parameters, followed by randomized controlled trials and prospective registries in humans with a sufficiently long follow-up period to reveal the potential advantages in clinical practice²¹.

The characteristics of ideal reinforcement on the hiatus are:

- to ensure durable and perfect reparation;
- perfect integration in the area's biodynamic;
- completely absorbable (fully disappearing from the body, in order to avoid long-term presence of foreign body);
- tolerance of infection, or positioning's possibility in a contaminated environment;
- no premature absorption in presence of bacteria;
- simple positioning;
- stable (no migration);
- possibility of use as bridge situations;
- cost-effective (accessible price);
- prevention of visceral complications (avoidance of adherences, fistulas, occlusions);
- resist shrinkage;
- promote minimal pain;
- non-carcinogenic.

Ideal mesh does not exist yet²⁴. Biological meshes, even proving good short-term results, haven't proved long term efficacy, while non-absorbable meshes might cause serious complications like erosion or migration. Reduction of HH's recurrence and reinterventions became a priority due to more complicated situations in these cases, with a higher incidence of complications. That's why it became necessary to study and evaluate biocompatible materials and techniques that could improve the results of hiatal hernia repair.

Platelet-rich plasma and its use in surgery

Recent studies on **platelet-rich plasma (PRP)** showed a positive effect on tissue remodeling and neovascularization, due to platelets' capacity of different proteins' liberation (growth factors, chemokine, cytokines etc.) that stimulates the tissue reparation²⁵. Independently of the role in thrombus formation during hemorrhage, the platelets attract cells that stimulate the tissue reparation (neutrophils, macrophages, stem cells etc.) through growth factors liberation, with consecutive activation of the intracellular cascade that generates migration, proliferation and diversification²⁶. The degranulation of the platelets' alpha-granules releases an increased number of growth factors, like platelet-derived growth factor (PDGF aa/bb/ab), transforming growth factor b1/2 (TGF-b1/2), vascular endothelial growth factor (VEGF), basic fibroblast growth factor (bFGF), platelet-derived epidermal growth factor (PDEGF), and insulin-like growth factor-I/II (IGF-I/II)^{25, 26, 27, 28}. Not only this, but platelets have a role in the immunomodulation and antiseptic proprieties. All these characteristics suggested the possibility of platelets' use in various surgical fields as adjuvant therapy.

The platelet-rich plasma PRP is a hemocomponent for local use, autologous or allogenic, obtained from the aggregation of a platelet concentrate put in contact with calcium and pro-aggregation biological (thrombin) or pharmacological factors^{25, 29}. The PRP is, basically, a super-concentrated form of platelets positioned in situ, on the lesion, in various surgical branches: oral and maxillo-facial, orthopedics and bone reconstructions, cutaneous ulcers, chronic

wounds, esthetic and plastic-reconstructive surgery, and ophthalmology^{30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40}.

The local use of PRP is favored by its characteristics like plasticity and possibility of modelling on the application spot. After its activation and platelets' degranulation, growth factors (GFs), chemokine and other bioactive metabolites are released, similar to the physiological process. These components could contribute to rapid reparation of abdominal wall defects due to the anabolic and chemotactic activity. There are reports on the PRP's efficacy on improvement of tissue response, on reduction of the incisional hernia's incidence and in reinforcement of tissue resistance^{41, 42}. Use of PRP in ventral hernia repair with acellular dermal matrices (biological mesh) as an autologous source of pro-regenerative growth-factors and chemokines was advocated in a rat model, due to the enhanced local angiogenesis, myofibroblast recruitment and tissue ingrowth. Further favorable effects as less severe peritoneal adhesions and diminished hernia recurrence might stimulate the use of PRP as an augmentation of the ventral hernia repair, with less recurrences and preserved mesh integrity⁴³.

Use of PRP in HH repair is anecdotal and only on animal models. Altieri reported the use of a filtered platelet concentrate on the HH's repair in pigs, after the surgical cruroplasty reinforced with the positioning of a biological mesh. Practically, the mesh was impregnated with the filtered platelet concentrate and this reparation was compared with 2 groups (control as simple surgical suture and reinforced cruroplasty without PRP). The hiatal area was histological analyzed and tensile strength testing was performed. A trend toward increased collagen deposition and vascularity in the filtered plasma concentrate group was shown, with increase tensile strength and yield force⁴⁴.

Improvement of the incidence of postoperative complications and recurrences after hiatal defects repair has a crucial importance. Our study proposes to confront a biosynthetic, absorbable mesh (Gore[®] Bio-A[®] Tissue Reinforcement) used for the reinforcement of

laparoscopic PC vs. the surgical repair reinforced by the application of an autologous platelet concentrate PRP in a porcine model of HH repair.

Tissue renewal and repair, as a pathological process, consists in regeneration (restitution of tissue components identical to those removed) and healing, a fibroproliferative response involving a number of processes: inflammatory reaction to the initial injury, with removal of damaged and dead tissue; proliferation and migration of parenchymal and connective tissue; angiogenesis and granulation tissue; collagen deposition; tissue remodeling; wound contraction and acquisition of wound strength. It was shown that Gore[®] Bio-A[®] tissue reinforcement scaffold was designed to break down primarily by hydrolysis. Within one to two weeks after positioning, the patient's cells migrate into the scaffold and begin generating vascularized soft tissue. Gradually over approximately 6 to seven months, the material is absorbed by the body and replaced 1:1 with the patient's own favorable type 1 collagen.

In the meantime, autologous PRP, having all the characteristics of a self-product, contains an array of growth factors and chemokines that can boost tissue healing^{25-27,44}.

Cristian Eugeniu Boru

3. AIMS OF THE STUDY

1. To establish a laparoscopic model of a hiatal defect in pigs
2. to analyze the hiatal area's HP modifications induced by the biosynthetic, absorbable mesh positioning as reinforcement of the laparoscopic posterior cruroplasty and its full absorption;
3. to analyze the hiatal area's histopathological HP modifications induced by the autologous platelet-rich plasma PRP positioning as reinforcement of the laparoscopic posterior cruroplasty and its absorption;
4. to evaluate the safety profile of the reinforcements (adhesions, infections, periesophageal fibrosis, distortion of the local anatomy, inflammatory pattern)

Rationale of the study: The rationale behind this experimental study is to evaluate the anatomical and HP pattern of the hiatal area after mesh and PRP absorption, because the use of meshes on the hiatus keeps on being controversial due to the severe complications related to their use and the recurrence's rate. The study proposes to evaluate if the PRP's application could improve the crural repair and the tissue remodeling in a porcine model of hiatal hernia repair. Proposed objectives of the reinforcement are:

- No recurrence;
- Increase of the security of the positioning near the esophagus;
- Tissue remodeling improvement, with stronger reparation.

The particularity of the study (justification): evaluation of a model, outcomes, pitfalls, and applicability to the clinical setting of an autologous hematologic product, adjuvant for soft tissue repair in abdominal or inguinal wall but applied in the HH repair. The PRP is compared with a mesh already used for this pathology. The literature is lacking in studies on the use of PRP in hiatal defects repair, with only one published study on a porcine model and one report of its

use in humans, with no comparative studies between autologous and biosynthetic reinforcement.

Justification of the animal model

The necessity of choosing the porcine model is based on the fact that the surgical procedure must reproduce faithfully human intraoperative conditions that surgeons should face during laparoscopic hiatal defects reparations. The porcine model is one of the most used between superior mammals, due to the genetically vicinity, being widely recognized as the most relevant pre-clinical model, based on the organs, physiology and digestive similarities⁴⁵. That's why it is hypothesized that the experimental surgery's results are transferable on human species and that is why the information gained cannot be obtained in different ways. Histological evaluations, gained on medium term, will offer original data useful for the medical industry's efforts on more and more affordable, efficient biomaterials production and use on esophago-gastric pathology.

4. MATERIALS AND METHODS:

4.1. TYPE OF STUDY

This is a pilot study, designed as a prospective, open, randomized study, performed on fourteen (n=14) young female Yorkshire pigs, aged 4-6 months, weighting 20-25 kg, obtained from an institutionally approved vendor. University “La Sapienza” of Rome, Faculty of Medicine and Pharmacy, Department of Medico-Surgical Sciences and Biotechnologies Board’s Committee approved the study’s experimental protocol, and ulterior it was approved even by the Minister of Health of Italy.

Pigs were acclimated after acquisition and operated in an advanced experimental center, Surgical Training Institute, located in Ponderas Academic Hospital, Bucharest Romania. Logistics, operating rooms fully equipped for laparoscopic approach and oro-tracheal intubations machines, and authorized animal manipulation by the National Health Minister of Romania were provided in this quality-controlled center. The center has over 18 years of experience in experimental surgery on animals, simulators and training.

Study groups:

Group B: Hiatal surgical suture (PC) + Bio-A[®] mesh: n=6 animals;
Group 2. Hiatal surgical suture (PC) + PRP: n=6 animals.

A biosynthetic, absorbable prosthetic mesh was considered for the study: a copolymer of polyglycolic acid (67%)- trimethylene carbonate (33%), GORE[®] Bio-A[®] Tissue reinforcement (W. L. Gore & Associates, Newark, NJ, USA) – was placed after posterior crural closure as reinforcement of the surgical procedure. The use of Bio-A[®] mesh in the reinforcement of the cruroplasty has already been reported (see table 1), with good results⁴⁶, with no local or general complications and tendency in reducing postoperative recurrence²⁰. The mesh is composed of a 3-dimensional web of polymers (figure 1), gradually absorbed over 6 months and replaced by vascularized soft tissue, due to the open, highly interconnected pores that facilitates cell infiltration and vascularization to generate quality tissue fast, leaving no permanent material behind. This

biodegradable mesh provides a temporary scaffold for ingrowth of native tissue and collagen deposition with no risk of contamination and infection. It does not require any preparation, such as soaking or stretching, and no special storage conditions. It was suggested that fully absorbable meshes with longer-term absorption profiles might provide improved mechanical and histological properties compared to biologically derived scaffolds⁴⁷.

4.2. PRP PREPARATION

The autologous PRP concentrate is prepared in concomitancy with the surgical procedure through a method that permits to obtain 2 fundamental elements: the platelets concentrate and the thrombin, the last one necessary for the platelets' activation and degranulation. The preparation procedure consists in 4 phases³⁸:

4.2.1 Autologous, full blood withdrawal

A 20 ml venous blood withdrawal was performed from the pigs randomized in the PRP reinforcement group, using jugular or femoral vein access, with a 20 Gauge needle and a 60 ml syringe preloaded with a sodium citrate, citric acid and dextrose anticoagulant solution (ACD-A, Salf SpA, Canate Sotto, Bergamo, Italia), in a 1:9 ratio. The ACD-A solution contains: 22.0 g/L bihydrate sodium citrate, 8.0 g/L mono hydrated citric acid, 24.5 g/L monohydrated glucose (dextrose) in i.v. sterile solution. A 10 ml additional quantity of autologous venous blood is withdrawal and distributed in 2 tubes of 5 ml each, containing sodium citrate as anticoagulant (Terumo Medical Corporation, Elton, MD, USA), in order to obtain the autologous thrombin.

4.2.2 Platelet rich plasma preparation

The 20 ml blood sample is divided in 2 tubes (Sterilin Ltd, Newport, UK). Both tubes are centrifuged (Rotina 46R, Hettich, Milano, Italia), in order to obtain various blood components' separation, based on their density. The plasma and buffy coat will be centrifuged again in order to obtain the platelet concentrate sedimentation (CP or platelet pellet) on the base of the tube and the platelet-poor plasma (PPP) above. Some of the PPP will be

discarded, leaving an 8 ml volume of PRP, obtained from the re-suspension of the CP in the PPP. Small quantities (0,5 ml) of blood and of final product are used in order to confront the platelets' concentrations (Cell Dyn 3500R, Abbott, Wiesbaden, Germania) and confirm the adequate platelets' therapeutically concentration⁴⁰.

4.2.3 Autologous thrombin preparation

Autologous blood contained in the 5 ml tubes with sodium citrate was centrifuged for 10 minutes. At this plasma fraction 10% calcium gluconate is added (446 mEq/l di Ca⁺⁺) (Monico SpA, Venezia-Mestre, Italia), in a 5:1 ratio. The plasma – calcium gluconate mixture is incubated at 37°C in CO₂ incubators a (NuAire DH Autoflow, Plymouth, MN, USA). The obtained clot is pressed, and the thrombin rich solution is collected for the next phase, the PRP activation.

4.2.4 The PRP activation

The PRP gel is obtained putting together the PRP, the thrombin rich solution and the calcium gluconate in an 8:1:0.5 ratio in about 10 min. The entire lab procedure is performed with sterile, single use materials, in asepsis conditions, under a hood of laminar flow (Bicasa, Barnareggio, MB, Italy), respecting the lab's good practice.

4.3 SURGICAL PROCEDURES

4.3.1 Phase one: first surgical intervention March 2018

Animals were fasted for at least 12 hours prior to surgery. An antibiotic (amoxicillin 15 mg/kg IM every 24 h) and anti-inflammatory therapy (flunixin meglumin 2,2 mg/kg IM every 24 h) was initialized in the day of surgery and followed for the next 5 days.

A clinical examination was performed, necessary for the clinical status confirmation (ASA I, American Society of Anesthesiologists classification⁴⁸), followed by i.m. premedication with a mixture of ketamine (5 mg/kg), xilazin (2.5 mg/kg) e butorfanolo (0.2 mg/kg), part of the multimodal anesthesiologic plan.

After tranquilization status was obtained (expressed by the

reduction of the psycho-motor response to manipulations) a central venous line was positioned near the auricular vein. General anesthesia was induced with thiopental sodium (6 mg/kg) and maintained on inhalator way through oro-tracheal intubation and mechanical ventilation, with a mixture of isoflurane in oxygen. These procedures guarantee a stable surgical anesthesia during all procedures, with the main aim to limit / cancel the consequent nociceptive stimuli. In case of anesthetic plan reduction (like cardiac frequency increasing, respiratory frequency increasing, blood pressure increment, muscular rigidity, voluntary movements), seen on clinical and instrumental monitoring, as routine during veterinary anesthesia, an adaptation of the treatment was done with supplements of analgesics and anesthetics.

A blood withdrawal was performed in the Group B before surgical procedure started, necessary for the PRP and thrombin production that followed the steps described above.

Animals were placed in dorsal recumbency, in anti-Trendelenburg position, and the ventral abdomen was prepared for aseptic survival surgery by shaving the entire abdominal region, cleaning the operative area with three alternating scrubs of povidone-iodine solution and 70% isopropyl alcohol solution, and applying sterilized surgical drapes over the entire field.

Following preparation of the abdomen, laparoscopy was performed using standard laparoscopic trocars and instruments: usually one optical trocar placed supra-umbilical, two 5 mm trocars laterally for the operating surgeon and one 5 mm in the epigastrium for liver/organs retraction. After pneumoperitoneum induction and exploration of the abdominal cavity, the hiatal area was exposed. Diaphragm's left crus was exposed after upper gastric greater curvature and gastro-phrenic ligament dissection, with mobilization of the gastric fundus. Short gastric vessels were partially resected in case of necessity of better gastric mobility using advanced electrosurgery (Ultracision, Ethicon Johnson & Johnson). Afterwards right crus was exposed and proper dissection of the esophagus was made in order to fully exposed the intra-abdominal

esophagus, eso-gastric junction and the retroesophageal window. Periesophageal dissection was completed in case of necessity.

In order to create an artificial hiatal defect, which can simulate real defects, a cut or partial excision of right crus was executed, with further dissection. The resulting defect was measured based on a simplified calculation of the hiatal surface area (HSA), with the area of a rhombus formula ($d_1 \times d_2 / 2$), and a surface up to 4 cm² was obtained (see figure 2).

Crura's suture: Repair of the iatrogenic hiatal defect was performed by laparoscopic suture of the hiatus (posterior cruroplasty PC, figure 3) with interrupted, non-absorbable stiches (2-0 polypropylene sutures, Ethicon, Cincinnati, OH, USA).

Reinforcement of crura suture: randomization between the two types of available reinforcement was computer generated (Excel, Microsoft): Bio-A[®] mesh (Group A) vs. PRP (Group B).

The absorbable, biosynthetic mesh was tailored for local use. Due to standard dimension (rectangle of 7X10 cm), its length was be reduced to 5/8 cm, cutting the left part of the mesh, creating a U-shape hole in the upper part of the mesh, in order to obtain an asymmetrical "U", leaving the right part longer than the left to obtain adequate right pillar reinforcement (figure 4) The "U" concavity was slightly enlarged downward to reduce the risk of possible contact with the esophagus. Then it was rolled like a cigarette and inserted through the 10-mm trocar, superimposed on the cruroplasty and fixed with Prolen 2/0 stiches. The incised part of the mesh (the so-called U) was positioned under the esophagus. Due to the total absorbable characteristics of the mesh and of the fixing devices, some titan clips were used for marking the covering area. These clips could have been useful for radiological identification as well.

In the Group B, an identical procedure was performed for the

preparation of the hiatal area. The autologous PRP was prepared concomitant with the surgical preparation of the hiatal area and PC in about 40 min. It was presented as a thick gel (figure 5), and it was positioned over the PC pillars, using a laparoscopic applier and fixed with absorbable stitches. Final image after reinforcement positioning over the PC is shown in figure 6.

4.3.2 Second phase: postoperative animals monitoring 03. 2018 – 09. 2018

After operation and 2 days recovery and strict monitoring, pigs were transferred, cured, raised and followed for the next 7 months in the stalls of a conventional animal farm, where they were routinely monitored, daily feed and routinely cleaned. Wounds were checked daily for the first 10 days, till stiches removal and full healing. Assistance was provided daily, according to the national regulations for animal testing (Allegato III del Decreto Legislativo 26/2014 regarding porcine housing), by a collaborating veterinary doctor, using the auxiliary models, see Table 2: Clinical card of daily monitoring. Grimace scale⁴⁹ (0 = not present, 1 = moderately present, 2 = obviously present), and Table 3: Body Condition Scoring⁵⁰. In case of significant variations of the monitored parameters, an increment of the monitoring and required therapy was applied. In case of medical issues that could became too painful for the animals or incompatible with life, euthanasia would have been performed before the ending of the study.

The humanitarian endpoints will consist in the following:

1. Grimace scale >15, or < 3 in the Body Condition Scoring;
2. External physical aspect: dehydration, necrosis and ulcers, edema, or surgical wound dehiscence;
3. Behavioral modifications: abatement and severe depression of the sensory, voluntary fasting.

4.3.2 Third phase: second surgical intervention Oct 2018

Pigs were returned to the operating rooms 12 weeks after primary operation, in the same Surgical Training Institute, located

in Ponderas Academic Hospital, Bucharest Romania. The animals were prepared to surgery in the same way like in phase 1, with oro-tracheal intubation and field preparation. Afterwards, laparoscopy was performed on the anesthetized pigs. After inspection of the abdominal cavity and dissection of the eventual adhesions, the hiatal area was exposed and video registration was performed, in order to demonstrate any modification of the hiatal area.

After video recording, the animals were sacrificed, being under general anesthesia. Euthanasia was obtained accordingly to the *American Veterinary Medical Association (AVMA)*⁵¹. Afterwards, laparotomy was performed, and all animals were visually checked for local effects like adhesions, stenosis, mesh presence, cruroplasty's previous sutures. In order to obtain a bigger specimen, like en-bloc resection of the hiatal area (thoracic and abdominal esophagus, diaphragm, periesophageal fat, hiatal crura containing the studied area), with full removal of the mesh-reinforced area, conversion to laparotomy was done for an easier and faster access. In this way we could demonstrate the full or partial absorption of the mesh and of the PRP. After inspection of the abdominal cavity and dissection of the eventual adhesions, the hiatal area was exposed and surgically removed (figure 7). The entire specimen was preserved in formalin solution 10% and prepared for transportation in refrigerated containers.

4.4 HISTOPATHOLOGICAL EXAMINATION

Specimens were transported to the Department of Morphology and Morphopathology, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest Romania, for the definitive histopathological diagnosis. The specimens were placed in a liquid fixing agent (fixative) such as formaldehyde solution (formalin). Following fixation, the specimens were dissected to select appropriate areas for examination. Processed specimens were placed in suitable labelled cassettes (small perforated baskets) to segregate them from other

specimens. Because melted paraffin wax is hydrophobic (immiscible with water), most of the water in a specimen must be removed before it can be infiltrated with wax. This process is commonly carried out by immersing specimens in a series of ethanol (alcohol) solutions of increasing concentration until pure, water-free alcohol is reached. The next step is clearing with xylene. This solvent will displace the ethanol in the tissue, then this in turn will be displaced by molten paraffin wax. Then the tissue was infiltrated with a suitable histological wax. After the specimen is thoroughly infiltrated with wax it must be formed into a “block” which can be clamped into a microtome for section cutting. This step was carried out using an “embedding center” where a mold was filled with molten wax and the specimen placed into it. After paraffin embedding, samples were sectioned at 3 μ m width using the microtome (Leika[®], Germany), mounted onto electrostatically treated glass slides (Bio-Optica[®], Milano, Italy), and stained with morphological stain hematoxylin and eosin (H&E) and special histochemical stains:

- Trichrome of Masson: this is a three-color staining protocol used for distinguishing cells from surrounding connective tissue. Most recipes produce red keratin and muscle fibers, blue or green collagen and bone, light red or pink cytoplasm, and dark brown to black cell nuclei.
- Alcian blue/Periodic Acid-Schiff (AB/PAS): is a staining method used to detect polysaccharides such as glycogen, and muco-substances such as glycoproteins, glycolipids and mucins in tissues. The reaction of periodic acid oxidizes the vicinal diols in these sugars, usually breaking up the bond between two adjacent carbons not involved in the glycosidic linkage or ring closure in the ring of the monosaccharide units that are parts of the long polysaccharides, and creating a pair of aldehydes at the two free tips of each broken monosaccharide ring. The oxidation condition has to be sufficiently regulated so as to not oxidize the aldehydes

further. These aldehydes then react with the Schiff reagent to give a purple-magenta color.

Alcian blue was used in combination with the PAS staining procedure, so that both acid and neutral mucins can be demonstrated in the same tissue sample. Alcian blue will stain acidic mucins blue and PAS will stain neutral mucins rose red.

All histological assessments were conducted by a board-certified, experienced veterinary pathologist in the Department of Morphopathology and Comparative Oncology, Faculty of Veterinary Medicine, Spiru Haret University, Bucharest and in the Department of Morphology and Morphopathology, Faculty of Veterinary Medicine, University of Agronomic Sciences and Veterinary Medicine, Bucharest, Romania. The following outcome measurements were assessed:

- resorption (disappearance of the reinforcement method from its initial place due to physical or chemical phenomena);
- degradation (loss of the performance or of the characteristics of device, regardless of the mechanism)
- organization of connective tissue, inflammatory response, tensile strength, and amount of adhesion formation.

In order to characterize the host inflammatory/fibrotic response, collagen deposition or remodeling and absorption proprieties associated with each specimen, based on a standardized scoring system, specimens were scored (proposal)²¹ using appropriately selected antibody panels, using the following parameters:

- Inflammatory infiltrated presence (leucocytes, neutrophils, eosinophils, macrophages, giant cells, lymphocytes) and its quantifications using the standard, International *scoring system* standard;
- Infiltration and organization pattern of inflammation (diffuse inflammation, granulomatous inflammation, etc.);
- Neo-angiogenesis (evaluated using the neoformation of an elaborate network of small vessels on the superficial unit,

after marking with VEGF, FVIII e CD31);

- Fibrosis (evaluated using the collagen characterization and of the organization factors – maturation of the same one: Collagen I, Collagen III, Decorin, Aggrecano, Metalloproteasis);
- Presence of necrosis phenomena, dystrophic calcification, chondroid metaplasia of the fibrotic areas and capillary microthrombosis.

For any parameter a score was attributed, obtained from the validated *scoring systems*, valued from 0 to 3, based on the response:

- absent (0);
- minimally or barely detectable (1);
- mild or easily detectable (2);
- marked / very evident (3).

In order to study the collagen networks (quantitative-qualitative analyze), slides were stained with H&E, Trichrome of Masson, AB/PAS: the quantity of the produced collagen and visualization of the organized grade of collagen fibers, both under microscope and under polarized light, whereas collagen bundles appear green, red or yellow, and are easily differentiated from the black background, thus allowing for quantitative morphometric analysis. Collagen was analyzed using mucopolysaccharides coloration, both neutral (PAS will stain neutral mucins rose red) and acid (AB will stain acidic mucins blue).

- a) Vascularization—Degree of vascularization was assessed histologically at 40X magnification by averaging the total number of blood vessels present on five non-overlapping fields of fibroconnective/ granulation tissue from site of the hiatal closure.
- b) Collagen deposition - A comparative analysis of collagen organization, abundance and myocyte degeneration based on H&E, Trichrome Mason and AB/PAS staining was performed. Based on existing literature, specimens were scored using a semiquantitative scale of 0–3, where a 0

reflected a complete absence of fibrosis and a 3 reflected broad bands of collagen deposition.

- c) Histologic examination of mesh or PRP hiatal interface zone: the degree of inflammation, manifested by infiltration of lymphocytes, macrophages, and plasma cells per high power field, was semiquantitative estimated by cell density and scored based on a scale of 0–3.

4.5 STATISTICAL CONSIDERATIONS

Statistical analysis

A minimal number of 12 animals is necessary (6 for each group) in order to obtain solid data for a significant statistical analyze. These numbers correspond with similar reports from the literature ¹⁹, where a study group of 4 subjects resulted as a limitation for the study (small sample size, with lack of calculation power) ^{21,26, 44, 47, 52}. The minimal number of subjects for each group was considered 6, due to the fact that our project confronts the histopathological modifications induced by two types of reinforcement. Due to the risks of intra- and postoperative incidents (like iatrogenic injuries, spontaneous deaths, postoperative medical conditions independent of the surgical procedure, etc.), with possible loss of subjects, 14 animals were considered the minimally indispensable number included in the study, in order to obtain valuable statistical data.

Sample Size

The purpose of this study was to assess the performance of the autologous PRP in covering the hiatal hernia repair and determine a durable local tissue ingrowth, in order to avoid recurrence, compared to a biosynthetic, absorbable Bio-A[®] mesh. The proposed sample size of 12 subjects, with multiple measurements taken per subject, are deemed sufficient to assess the safety and performance of the mesh with respect to the data collected for the primary endpoint.

Data Analysis for the criteria presented in the primary endpoint.

Study data were summarized mainly with descriptive statistics, where continuous data were summarized by a mean standard deviation, minimum, median and maximum. Discrete data will be presented as a count and percentage. Continuous measurements were compared with the Wilcoxon rank test. The level of statistical tests' significance will be considered achieved with $P \leq 0.05$.

The cumulative incidence (and 95% CI) of device-related complications and adverse events (AEs) observed intraoperative and throughout the follow-up period, are presented in a tabular format. A detailed list of all adverse events will be presented, if recorded. The adverse event rate will be compiled with respect to frequency, nature, severity of the event, and relationship to the study device. In addition, listings of all safety measures will be produced.

5. RESULTS

Twelve animals survived after the laparoscopic surgery and were sacrificed 7 months later (28 weeks), 6 for each study group. Two animals died during the laparoscopic procedure, one suffered a tension bilateral pneumothorax, and one did not recover spontaneous respirations following extubating. The autopsy of the two animals confirmed the suspected diagnosis by the anesthesiologist. The long-term survival animals had a normal postoperative evolution, with normal wounds healing, stable weight gain and no pathology under veterinary surveillance in a proper recovery animal farm.

The estimated time of the laparoscopic surgery was 60 minutes, with no difference between the 2 groups. Time spent with mesh tailoring, insertion in the abdominal cavity through the trocar, position and fixation over the posterior cruroplasty in group A was comparable with the time consumed by PRP clot intraabdominal insertion, position and fixation in group B (mean operative time 15 min for each group). The mean concentration of therapeutic PRP was 10^6 platelets in 1 μ l of plasma.

All surviving animals completed laparoscopically all the planned steps of the procedure. The second operation was performed as scheduled 7 months afterwards in all animals. At macroscopic examination of the abdominal cavity and hiatal surface area and palpation, no animal had local complications or possible side effects (obstructions, esophageal stenosis or kinking, intense adhesions or hiatal hypertrophy, anatomic distortion of the hiatal surface area). No failure of the posterior cruroplasty was registered for both groups. In particular, in the group A no residual mesh on the hiatus was observed at gross examination, but more adhesions vs group B (see figure 8) were evident. Thereafter, mild reactive ascites and hepatic hilum lymph nodes enlargement were evident. In group B there was no residual PRP on the hiatus as well (figure 8).

5.1 Histopathological results

A full resorption of both Bio-A® mesh and autologous PRP was observed at HP examination at 7 months. Results of the HP interpretation were classified based on following components (see table 4):

- ***Proliferative fibroblast – fibrocyte – collagen - neoformation component:*** both groups presented cellular (fibroblasts and fibrocytes) and neo-fibril-conjunctively parts (collagen PAS +, alcian blue +, Trichrome Masson+), with predominance in the Bio-A group, shown and interpreted in figures 9 and 10. Neo-collagen fibers, disposed parallel, are presented in increased number in group A in the connective tissue, with consequent muscular fibers' dissociation and creating the premises for an intense sclerosis area.
- ***Vascular component:***
Group A (figure 11): Endothelial cells of the neo-formed vessels are plump, presented large nuclei and showed numerous pycnotic vesicles that were also observed in the subendothelial pericytes, (different calibers), intense and diffuse active hyperemia, both arterioles and veins ± perivascular hematic extravasation; endothelitis and sclerogenic thrombo-arteriopathy, with collagen fibers proliferations mainly PAS positive and alcian blue weak positivity.
Group B (figure 12): Only neovascularization phenomenon, with relatively frequent aspects of active hyperemia.
- ***Inflammatory component (chronic nodular aspect mainly, with rare acute or sub-acute zones)***
Group A (figure 13): Granulocytes, neutrophils and eosinophils, mononuclear cells like lymphocytes, plasmocytes, macrophages and histiocytes.
Group B (figure 14): Present only in the conjunctive tissue,

organized as nodular chronic inflammation, with lymphoplasmacytes and mono-histiocytes cells.

- ***Dystrophic component similar for both groups (shown and interpreted in figure 15):*** The most intense and evident, localized on the crura, with skeletal muscle degeneration, vascular lesions and of adipose metaplasia.

A semiquantitative histological scoring of tissue reaction was elaborated based on the above results (see table 5), calculated based on:

- inflammation 0 = absent, 1 = mild detectable, 2 = present, 3 = marked/very evident;
- fibrosis (collagen, fibroblast, fibrocytes): 0= absent, 1 slightly detectable, 2 mild, 3 marked;
- vascularization: 0 = absent, 1= rare, 2 = some vessels (3-5), 3 = over 5 vessels.

Based on this semiquantitative HP scores, animals in the mesh group showed an increased pattern of chronic inflammation (2.66 vs. 1.83, $p = 0.04$) compared to PRP group. Vascular and collagen network did not differ between groups ($p = 0.306$), although there was an increased trend toward mean collagen fibers in the mesh group (2.83 ± 0.4) compared to PRP (2.33 ± 0.81).

As a summary of the observed pattern, in group A there was an evident inflammatory reaction, composed from mononuclear inflammatory cells located between young collagen fibers, disposed parallel, and edged by hyperemic capillaries with rare hematic extravasations (granulation tissue). The adjacent muscles are marked by fibroblast proliferations, with interfibrillar connective tissue's accumulation. From the point of view of the phenomenon of sclerogenic collagenization of interstitial connective tissue, meshed pigs recognized a larger process, respectively 2.83 compared to 2.33 in those without mesh.

In group B the inflammatory reaction was characterized by the active fibroblasts in the connective tissue, with young collagen fibers, with neovascularization phenomenon (different calibers), with relatively frequent aspects of active hyperemia. This group was characterized by less inflammatory response compared with group A, but an important fibrosis phenomenon (collagen, fibroblast, fibrocytes) and neovascularization were seen as well, creating the premises of tissue remodeling and improved healing.

5.2 Statistical analysis results

Results of the semiquantitative histological scoring of tissue reaction statistical analyze between the 2 groups are reported in Table 5 and Figure 16 for each variable examined. There was no statistically significant difference between the 2 groups. For each variable, there is a minimum, 1st quartile, median, mean, 3rd quartile and maxim reported. Wilcoxon non-parametric test was used, but chi quadro test as well and they are reported in table 5.

1. For the “inflammatory response” variable

Mesh group		1st Qu.	Median	Mean	3rd
Min.	Max.				
2.000	3.000	2.250	3.000	2.667	3.000
PRP group`		1st Qu.	Median	Mean	3rd
Min.	Max.				
0.000	3.000	1.250	2.000	1.833	2.750
Mesh group	PRP group				
0	0	1			
1	0	1			
2	2	2			
3	4	2			

2. For the “Vascularization” variable

Mesh group`					
Min.	1st Qu.	Median	Mean	3rd	
Qu. Max.					
1.000	2.000	2.000	2.167	2.750	
	3.000				
PRP group`					
Min.	1st Qu.	Median	Mean	3rd	
Qu. Max.					
1.000	1.000	1.500	1.667	2.000	
	3.000				

Mesh group	PRP group	
1	1	3
2	3	2
3	2	1

3. For the “Fibrosis” variable

Mesh group					
Min.	1st Qu.	Median	Mean	3rd	
Qu. Max.					
2.000	3.000	3.000	2.833	3.000	
	3.000				
PRP group					
Min.	1st Qu.	Median	Mean	3rd	
Qu. Max.					
1.000	2.000	2.500	2.333	3.000	
	3.000				

Mesh group	PRP group	
1	0	1
2	1	2
3	5	3

Cristian Eugeniu Boru

Pag 36

6. DISCUSSION

The results of the present experimental study demonstrate that a reliable big animal model for the study of hiatal surface area pathology can be set up also using a minimally invasive approach. The highlight of the study from the technical point of view are:

1. A devoted anesthesiologist is mandatory to obtain a high survival rate considering the specific physiopathology related to laparoscopy and induced pneumoperitoneum;
2. The laparoscopic approach to the hiatal area can be standardized in the pig, obtaining a reliable defect of the hiatus mimicking the human hiatal hernia;
3. A standard cruroplasty can be carried out in the pig with a proper reconstruction of the hiatal surface area diameter;
4. The coverage of the cruroplasty and the hiatal area by reinforcement material is feasible and safe in this animal model;
5. This experimental animal model can be used for further study of the hiatal area using different autologous or heterologous material.
6. The tissue harvesting technique was standardized allowing proper histopathological examination.

Coming back to the rationale of this pilot study, a fundamental question remains regarding the etiology of HH: is it caused by the mechanical stress to which the gastroesophageal junction (GEJ) is exposed and/or is related to a biological change in the structures of this region, such as the crura of the diaphragm and as the fixation structures around of the GEJ (gastrohepatic ligament, gastrophrenic ligament, and periesophageal ligament)? Fei et al showed that patients with hiatal hernia have ultrastructural abnormalities at the crura's muscular tissue that are not present in patients with a normal GEJ: dilation of intermyofibrillar spaces, swelling of sarcotubular structures, focal degeneration of

myofibrils, and extended disruption and degeneration of the muscle's architecture⁶. All these findings suggested signs of structural weakness in the crura of the patients with HH, that might be the cause of recurrence after primary surgical repair.

Regarding the periesophageal ligament, Fei didn't find any difference in the microscopic damage at the connective tissue of the phrenoesophageal membrane surrounding the esophagus in normal subjects and HH patients. But von Diemen showed on biopsies obtained from the phrenoesophageal membrane in patients undergoing HH surgical treatment that the collagen content is reduced when compared with healthy subjects⁵³. Levels of total, type-I, and type-III collagens are reduced by about 60% at this level in patients with GERD and HH compared to cadavers without HH. Thus, the quality of the periesophageal ligament may be an etiological factor in the development of HH and/or could facilitate the occurrence of GERD in patients with GERD but without an associated HH.

Thus, the outcomes of the anti-reflux surgery could depend not only on the adopted surgical technique but also on the underlying status of the diaphragmatic crura. Surgical treatment of the hiatal hernia consists of dissection of the hernial sac from the mediastinum into the abdomen, followed by cruroplasty with sutures and fundoplication, with demonstrated acceptable morbidity and low symptomatic recurrence rates^{3,4}. A higher than expected radiologic, asymptomatic recurrent hiatal hernia was reported, with rates up to 30–42%, while 5-13% of these patients had symptomatic recurrence, that can require surgical revision in 5-10% of the cases^{19,54}. Even an asymptomatic recurrence may become symptomatic over time and can lead to severe complications. Currently, non-resorbable biosynthetic meshes are not routinely used anymore for HH's repair due to possible severe local complications determined by a chronic inflammatory response. This response can cause symptoms like chronic postoperative pain, discomfort, and mesh erosion, sometimes underestimated⁵⁴. Under these circumstances, biological meshes are possibly an alternative

for the most complex cases, especially in patients at risk for complications of infection. Unfortunately, these biological meshes seem to provide insufficient strength for adequate repair, and in addition, the costs of this variety of meshes are extremely high^{21,22}. Due to the disadvantages of both biosynthetic and biological meshes, strategies focused on the development of new type of mesh, like slowly resorbable biosynthetic meshes, were gradually introduced. This new generation of meshes aims to combine the advantages of both a biosynthetic mesh (no degradation shortly after implantation) and a biological mesh (the “remodeling” aspects and the better tolerance in case of contamination).

Some reports doubt about the efficacy of mesh use during hiatal hernia’s repair. It was shown in a cohort of 189 cases that radiologic recurrences, symptomatic recurrences and reoperation rates were equal after laparoscopic hiatal hernia repair with or without non-absorbable mesh reinforcement, irrespective of hernia’s size and type⁵⁵. Quality of life, dysphagia and patient satisfaction were comparable, with no serious mesh-related complications occurred. More favorable conclusions in term of mesh-use were highlighted by a recent review and meta-analysis conducted⁵⁶ on 942 patients, demonstrating that mesh hiatoplasty and sutured hiatoplasty produced comparable results with regards to reoperation rate and complications following the repair of paraesophageal hernias (POH), with significant recurrence’s reduction following use of mesh. All kinds of mesh were included in this study, from non-absorbable to biologic. Authors concluded that in the future a number of issues need to be addressed to determine the clinical outcomes, safety, and effectiveness of these 2 methods for elective surgical treatment of large hiatal hernias. These include:

- standardized definition of hiatal hernia’s dimension; our group recently introduced the Hiatal Surface Area CT-scan measurement as a useful, minimally invasive tool in hiatal hernia’s treatment of obese patients undergoing anti-reflux

surgery¹⁰. Nevertheless, the suggested cut-off HSA > 4 cm² was proved to be effective on the choice of when to apply the reinforced cruroplasty²⁰;

- standardized techniques of suture and prosthetic repair;
- type of prosthesis used: biologic/nonabsorbable/biosynthetic absorbable;
- standardized method of securing the mesh such as use of sutures, tacks, or biologic glues;
- standardized classification of recurrent hiatal hernia post repair;
- long term postoperative data collection of at least 5 years to detect the true incidence of hiatal hernia recurrence, reoperation and mesh migration or erosion between suture cruroplasty and prosthetic hiatal herniorrhaphy.

Still, the presence of a foreign body, the costs of these devices, the surgical skills needed for positioning, and nevertheless, patient's choice, made us look for other available solutions for the augmented, reinforced surgical treatment of the HH in order to obtain a reproducible technique. The use of an autologous, simple and cheap product like PRP might be an important adjuvant of the surgical cure. In the last years it was highly demonstrated the recurrences' reduction of hiatal hernia after cruroplasty's reinforcement. An autologous product, with similar proprieties like a certified mesh for local tissue remodeling, totally absorbable and with minimal impact on the nearby organs, it is for long time waited for the guarantee of a minor physical and psychological impact, faster recovery and reduction of the social burden. This is the first study that compares in an animal model the autologous PRP clot, like a self-standing procedure, with an already established surgical solution, the biosynthetic, absorbable Gore® Bio-A® mesh implant for hiatal hernia's repair. The study proposed to offer experimental answers with impact on the public health for the management of this pathology, definition of the technical indications and reduction of the expensive prosthetic materials waste. Long term benefits are easily understood because the use of new products, like autologous

PRP, laparoscopic dispenser, and of a new surgical technique, like laparoscopic application of PRP on the cruroplasty, might improve the results of surgical cure of symptomatic HH and GERD, pathologies that represents the most prevalent gastrointestinal disturb worldwide.

Studies published recently concentrated on the use of PRP in ventral (VHR) or inguinal hernia's reparation, with promising results. PRP was used as reinforcement of mesh repair of abdominal wall's iatrogenic defects in 12 dogs and compared with mesh alone repair group of 12 animals⁵⁷. Hernia's recurrence was not recorded in PRP-treated dogs, that also displayed significantly more neovascularization and less severe adhesion to the underlying structures in comparison to control group. Histological and molecular evaluation confirmed the gross findings that collagen deposition, new vessel formation, and overexpression of angiogenic and myofibroblastic genes were observed more frequently in the PRP group. In conclusion, the Authors found that addition of allogenic PRP in mesh enhanced neo-vessels formation, and increased tissue deposition and incorporation, with subsequent reduction of the peritoneal adhesion and of the recurrence rate.

Fernandez-Moure et co studied the effect of PRP on a porcine non-crosslinked acellular dermal matrix (ADM) in an *in vivo* model of VHR, hypothesizing that PRP would enhance ADM-tissue incorporation in a rat model⁵⁸. Enhanced neo-vascularization was associated with earlier and greater tissue deposition on the ADM. This suggested for the Authors that PRP could be used as an adjunct to VHR in clinical scenarios where poor wound healing is anticipated, and enhanced neovascularization and early tissue deposition is desired. Same Authors hypothesized that recurrence after VHR remains a multifactorial problem due to mechanical strain, poor tissue-mesh integration, and degradation of matrices⁴³. The high recurrence rate witnessed with the use of ADM for definitive hernia repair has reduced their use largely to bridging repair and breast reconstruction. Use of PRP might improve classic

cellular metrics of successful VHR, resulting in improved rates of hernia's recurrence. The study consisted in reparation with Strattice™ (Allergan, USA) mesh alone or impregnated with PRP in 32 Lewis rats with surgically induced, chronic ventral hernias. Samples were harvested at 3 and 6 months postoperatively and compared for gross, histologic, and molecular outcomes of: neovascularization, tissue incorporation, peritoneal adhesions, hernia recurrence, and residual mesh thickness. PRP was shown to be an autologous source of pro-regenerative growth factors and chemokines uniquely suited to soft tissue wound healing, enhanced angiogenesis, myofibroblast recruitment and tissue ingrowth, ADM preservation, less severe peritoneal adhesions, and diminished hernia recurrence. Authors advocated further investigation regarding PRP augmentation of human VHR.

The effect of PRP-gel coating of polypropylene mesh on inflammation, production of collagen, and on smooth muscle was analyzed in the rabbit vagina by Parizzi et al⁵⁹. They analyzed 3 groups (sham, mesh only and mesh coated by PRP). The inflammatory infiltrate was evaluated using H&E staining, the Sirius Red stain to examine deposition of collagen I and III, and Masson's trichrome staining was used to visualize the smooth muscle. The group with PRP-coated meshes had a lower inflammatory infiltrate count at 30 days, deposition of collagen III increased with the use of PRP-coating at 90 days. The inflammatory component was significantly increased in the group without the PRP-coated mesh at 30 days but not in the group with the PRP-coated mesh, indicating a less intense inflammatory response.

There's only one study in a porcine model on the use of PRP in hiatal hernia's repair. Altieri analyzed recently⁴¹ on 3 groups of young pigs on which a iatrogenic defect of the hiatal area was created laparoscopically and then repair consisted on: hiatus repair alone (HR; n = 7 animals); hiatus repair and acellular dermal matrix (HRM; n = 8); hiatus repair and acellular dermal matrix and filtered plasma concentrate (fPC) (n = 9). Histopathological and

biomechanical analysis performed after 8 weeks showed that there was both a trend toward increased collagen deposition and tissue neo-vascularization, and that the mechanical strength of a hiatal defect reparation simulated in a porcine model can be improved upon addition of a biologic mesh. This mechanical resilience can be further enhanced with the administration of autologous platelet concentrate filtered from a modest amount of peripheral blood, thus accelerating the wound-healing process and encouraging healthier tissue regeneration than that observed through traditional defect repair. Tissue samples in the fPC group had a significant increase in tensile strength and yield force ($p < 0.01$) group in addition to ultimate strength.

There is only one reported study on the use of PRP in humans, where PRP was used as co-adjutant of mesh reinforcement of large HH's repair. Hrubnik et al evaluated the usefulness of PRP with self-fixated ProGrip™ mesh (Medtronic, USA) positioned in hiatal hernia's repair in a study on 144 patients with gastroesophageal reflux and large hiatal hernias (the size of hernias 10-20 cm²), who underwent Nissen fundoplication and PC⁶⁰. Patients were divided into two groups: I group, 71 patients with nonabsorbable self-fixating ProGrip™ mesh for reinforcement of PC vs. group II, 73 patients – simple PC. In I group “U”-shape tailored pieces of mesh were impregnated for 10 minutes in unfiltered 2-4 ml concentrate of autologous PRP and applied onlay over the PC, without further fixing materials like glue or stiches.

Follow-up was completed in 88,9% patients, with a mean duration of 39 months (range 12-60 months). 2 recurrences occurred in the mesh group and 14 recurrences appeared in the non-mesh group ($p < 0.05$). The use of PRP provided a fast ingrowth of mesh, acted as a catalyst to increase collagen synthesis and deposition, in order to promote decrease of recurrence's risk. With the use of PRP, the fixation process has become easier, faster and requires less concentration from the surgeon. The mesh structure is ideal for the use of PRP, which has become a good alternative to the use of

biological glue. Due to the increased stimulation of fibroblast growth, the mesh is quickly installed and has a reliable fixation. Stimulation of collagen synthesis prevents recurrence. There were no recurrences in the study group due to good mesh fixation. This study did not reveal any side effects when using PRP in laparoscopic treatment of large HH, proving the appropriateness of using self-adhesive mesh ProGrip™ covered with PRP to prevent recurrences.

In our study the use of PRP was compared with a biosynthetic mesh positioned on an iatrogenic defect in an animal model of HH's repair, based on a HP examination and a semiquantative score of local modifications. PRP preparation, positioning and fixation in the area of the surgical repair was performed after the surgical induced hiatal defect was closed, as in the mesh group, with no intraoperative or postoperative side-effects or complications. Survival of the animals for the next 7 months was uneventful. Promising HP data showed that the positioning of the autologous platelet concentrate provided from a modest amount of peripheral blood might accelerate the wound-healing process and stimulating better tissue regeneration.

Bioprosthetic cellular infiltration is a critical metric of the incorporation. Mesh group showed a higher score of cellular infiltration (2,83 vs 2,33). Both reinforcements determined inflammatory infiltrates predominantly mononuclear detected 7 months after positioning. Vessel ingrowth is known to be a strong predictor of incorporation, subsequent resistance to infection and increased mechanical strength. Mesh group showed a better neovascularization developed on 3 sub-components (2.16 vs 1.83), with intense and wide-spread active hyperemia. A stronger inflammatory response was shown in the mesh group (both macroscopic and at HP examination), creating temporary local conditions of non-self. Not only this, but the PRP group showed only signs of chronic inflammation, while the mesh determined even rare acute or sub-acute zones of inflammation, with granulocytes, neutrophils and eosinophils and this could be interpreted as a longer

local presence. Score for inflammation was slight increase in mesh group but without statistically significance.

Collagen formation (HE, Masson and PAS +) was demonstrated for both groups. In the PRP group, but mesh also, the muscular dystrophic changes were compensatory hypertrophy due to fibrosis between the muscular fibers. It remains to clarify if the local dystrophy is caused by the reinforced or other local process, determined by the quality of the hosts. No significant changes in fibrosis and also granulation tissue scores were observed between the two groups.

Bio-A[®] mesh was completely resorbed 7 months after positioning, as stated previously by the producers, demonstrated by the HP evidence and it was replaced by new tissues. The local remodeling consisted in increased local collagen aggregation, necessary for the efficient healing and demonstrated by the cellular infiltration, neovascularization. The border of the grafted material and the surrounding soft tissue could hardly be distinguished, which showed that the mesh had good biocompatibility with diaphragmatic crura e periesophageal tissue. This unique “second look” at a clinical site of implantation of Gore[®] Bio-A[®] Tissue Reinforcement showed that the material was entirely absorbed within 7 months and replaced by fibrovascular tissue. Use of absorbable biosynthetic mesh has the potential to avoid long-term complications associated with nonabsorbable mesh. Gore[®] Bio-A[®] Tissue Reinforcement has the advantages of a biologic mesh without the disadvantages of limited self-life, high cost, or need of preparation.

There are some limitations to our study: sample size maybe too small to reach statistical significance and no control group included in the study (surgical reparation without mesh or PRP reinforcement), and this was determined by the budget restrictions and nevertheless, the handling issues raised by the veterinaries and anesthesiologists and manipulating personal with animals after the 7 months follow-up, when animals reached up to 12 months of life and a weight ranging 80-100 kg.

The first limitation is on the choice of the study groups, a control group with suture repair only is lacking. This group would have accounted for the findings in the PRP group that have no comparative group. Indeed, the correct interpretation of the results indicates that the Bio-A[®] induces more significant collagen production than the PRP. Although this is interesting information in itself, the question whether the PRP induces any significant modification with respect to standard suture repair (no PRP, no mesh) remains unanswered for now.

The second point is the number of animals required in each group. Although it is clear that ethical and financial issues determined the number of animals included in the study, it is clearly stated that this is a pilot study, investigating a novel technique of repair and with a new approach.

Other limitations are determined by the lack of specific markers and immunohistochemical analyze, but, again, this is a pilot study and IHC is supposed to be performed later. The statistical analyze was performed on a minimum accepted number of each group's participants. There was a trend of increased vascularity and collagen deposition in the mesh group, without reaching a statistically significant difference. Furthermore, this was an experimental study, and the iatrogenic defect induced during surgery, with a calculated area of less than 4 cm², was not caused by a pathological condition, so the degree to which tissue integrity and function might return to normal is modified by the quality of the local tissues (presumed healthy in these animals), and by the dimensions of the defect (similar in all cases, due to the iatrogenic origin).

7. CONCLUSIONS

As a summary, our laparoscopic, animal model of hiatal hernia repair was reliable, feasible and reproducible. The comparative study of both materials, autologous and biosynthetic, did not show any specific complications (stenosis, kinking, perforations, animal sufferance) and there was no residual material found after 7 months. Speaking from the point of sclerotic collagenizing process of the interstitial connective tissue, the mesh group showed a more important score (2.83 vs 2.33).

These are the first data on the local modifications induced after more than 7 months by the biosynthetic, absorbable mesh on the hiatal area, confirming the safety, biocompatibility and tissue remodeling; in the same time modifications induced by the PRP gel application over the posterior cruroplasty are original and unique, and confirming the trend toward increased collagen deposition and vascularity of the connective tissue and muscles, but with less inflammation. Interstitial-muscular necrosis is represented only in animals treated with mesh, which denotes the existence of an irritating phenomenon, amended by the thrombocyte concentrate use in pigs without mesh.

PRP was shown to be an autologous source of pro-regenerative growth factors and chemokines uniquely suited to hiatal area wound healing, enhanced angiogenesis, myofibroblast recruitment and tissue ingrowth and less severe peritoneal adhesions. These results are creating the premises of the use of PRP as a promising co-adjuvant to local remodeling and healing in this animal model of hernia repair.

The study didn't provide any abnormal result, so we can continue our research. Next step will be the diaphragmatic muscular fibers' electron microscope evaluation, using control groups (no reinforcement) and PRP-mesh group, based on the fact that the interstitial-muscular necrosis phenomena was less important in the PRP group compared with the mesh one, probably attenuated by the

use of autologous thrombocyte's concentrate. This might show that the use of PRP could improve crura's weakness.

In conclusion, the results of the present pilot experimental study encourage further research protocol considering the reliable model of hiatal hernia and the laparoscopic steps of the procedures.

Once again is mandatory a cooperation with pathologist, bioengineer, industry for the proper testing of new tool for the reinforcement of the hiatal defect. The knowledge of the histological pattern at long term after repair is mandatory in the view of translation medicine. We consider this a first step in our research focused on the topic. Further investigation should confirm the onlay mesh positioning using PRP as glue fixation method in order to enhance the local tissue remodeling and healing.

8. FIGURES

Figure 1: copolymer web in the structure of the absorbable, 100% biosynthetic mesh used in the study Gore® BioA® tissue reinforcement (SEM X100, a) compared with natural collagen gel (b). Courtesy of Gore® Italy.





Figure 2: intraoperative photo showing the hiatal region, with retro-esophageal window and induced hiatal defect.



Cristian Eugeniu Boru

Pag 50

Figure 3: iatrogenic hiatal defect repaired by posterior cruroplasty.





Figure 4: Bio-A[®] biosynthetic, absorbable mesh used during the study. The mesh is “U” shape preformatted for the right position under the esophagus, covering the diaphragmatic crura. Courtesy of Gore[®] Italy.



Cristian Eugeniu Boru

Pag 52

Figure 5: autologous PRP clot prepared during the procedure.





Figure 6: Bio-A® mesh positioned over the posterior cruroplasty (photo a) and PRP concentrate positioned over cruroplasty (photo b).




Cristian Eugeniu Boru

Pag 54

Figure 7: intraoperative gross examination of the hiatal area, with more adherences in the group A (photo a) respect to Group B (photo b).



Figure 8 surgical specimens




Cristian Eugeniu Boru

Pag 56

Figure 9: Proliferative fibroblast – fibrocyte – collagen - neoformation component in mesh group, and direct local consequences:

- an intense fibroblast - fibrocystic cell activity is identified on a background of an intense collagenization; cellular score 3, collagen score 4; Alcian blue/PAS stain 60x (photo a);
- diaphragmatic pillar, muscular fibers strongly dissociated from a dense collagenic structure with the presence of necrotic areas; collagenization score 4, necrosis score 2; Trichrome Masson stain 20x (photo b);
- Diaphragmatic pillar, strongly hyperplasia interfascicular beams, with non-collagen formation; fibroblast-fibrocyte proliferation is moderate; collagenization score 3, fibroblast-fibrocyte cell score 2, Alcian blue/PAS stain 20x (photo c);
- On the background of an important necrosis of the interstitial tissue, there is a massive conjunctival sclerosis, with an area of vascular neoformation; necrosis score 2, collagenization score 4, vascular neoformation score 4; Trichrome Masson stain 60x (photo d).




Cristian Eugeniu Boru

Pag 58

Figure 10: Proliferative fibroblast – fibrocyte – collagen - neoformation component in PRP group, and direct local consequences.

- diaphragmatic pillar, collagenization process; collagen score 3; Trichrome Masson stain 20x (photo a);
- important collagenization of the muscular tissue from the diaphragmatic pillars; collagen score 4; Trichrome Masson stain 60x (photo b);
- minimal fibroblast-fibrocyte representation; fibroblast score 2; fibrocyte score 1; H.E. staining 60x (photo c);
- Zone of vascular neoformation and strong interstitial collagenization; collagen score 4, vascular neoformation score 4; Trichrome Masson stain 60x (photo d).




Cristian Eugeniu Boru

Pag 60

Figure 11 vascular component in the mesh group:

- neovascularization zone in the muscular interstitial, with intense collagenization and granulation tissue; collagenization score 3, granulation tissue score 2, neovascularization score 2; Trichrome Masson stain 60x (photo a);
- atherosclerosis lesions accompanied by thrombotic phenomenon, with necrotic periarterial area, atherosclerosis score 4; Alcian blue/PAS –stain 60x (photo b);
- venule in interstitial tissue, with hemato-leukocytic thrombus and an important inflammatory, perivascular area; inflammatory tissue score 2; vascular stasis and adventicia's inflammation H.E. stain 60x (photo c);
- severe stasis congestion, with area of perivascular inflammation; congestion score 4, inflammation score 3; H.E. stain 60x (photo d).




Cristian Eugeniu Boru

Pag 62

Figure 12 vascular component in the PRP group

- interstitial connective tissue with blood vessels, having a collagen deposit; Alcian blue/PAS stain 60x (photo a, c);
- structure of a thick-walled venule with lysed endothelium, having a large amount of hematoma at the intra- and extravascular level; H.E. stain 60x (photo b);






Cristian Eugeniu Boru

Pag 64


Figure 13 mixt inflammatory and vascular component in the mesh group: **a & b** perivascular; **c & d** in the connective tissue; **e & f** in the pillars

- zone of lympho-macrophage inflammation; thrombosed venule, with strong sclerosis of the wall, located in the central area of the image; inflammation score 3, lymphocyte score 4, macrophage score 2; Alcian blue/PAS –stain 60x (photo a)
- Eosin-macrophage inflammatory node, in the connective tissue, which centers a congested venule; inflammation score 3, macrophage score 1, eosinophil score 4; intense fibroblastic activity; H.E. stain 60x (photo b);
- inflammatory node together with free cells, disseminated in the connective tissue; presence of congestive neoformation structures; lymphocyte score 3, macrophage score 2, inflammatory tissue score 2; H.E. stain 60x (photo c);
- Inflammatory process in the connective tissue with the presence of congestive neoformation structures; lymphocyte score 3, macrophage score 2, inflammatory tissue score 2; Trichrome Masson stain 60x (photo d);
- diaphragmatic pillars - massive collagenization, with diffuse, inflammatory nodular areas; inflammation score 4, collagenization score 4, lymphocyte score 4, macrophage score 3; Trichrome Masson stain 20x (photo e);
- diaphragmatic pillars - diffuse inflammatory area in the interfascicular tissue; H.E. stain 20x (photo f).







c



d




e



f

Figure 14 mixt inflammatory and vascular component in the PRP group: **a, b, c** in the connective tissue, **d** in the pillars.

- photo a: connective tissue infiltrated with chronic inflammatory cells; lymphocyte score 1, macrophage score 2, fibroblast score 3, fibrocyte score 2; H.E. stain 60x;
- photo b: chronic interstitial inflammatory process; lymphocyte score 1, macrophage score 2, fibroblast score 3, fibrocyte score 2; H.E. stain 60x;
- photo c: myxomatous proliferation at the level of connective tissue; myxomatous cell score 2; Trichrome Masson stain 60x;
- photo d: diaphragmatic pillars, important area of chronic inflammatory in the connective tissue; inflammation score 4; H.E. stain 20x.



Cristian Eugeniu Boru

Pag 68

Figure 15: dystrophic component:

- Mesh group diaphragmatic pillars, striated muscle tissue infiltrated with numerous necrotic areas; necrosis score 4; H.E. stain 20x;
- PRP group section through the diaphragmatic pillars where a large dystrophic-necrotic area is noted as a consequence of a chronic inflammatory process; H.E. stain 20x (photo b);
- PRP group minimal inflammatory process present in the connective tissue; in the dystrophic-necrotic areas, a collagenic remodeling is observed; Alcian blue/PAS stain 60x (photo c).







Figure 16: Statistical analyze for each variable examined: inflammatory response (a), neovascularization (b) and fibrosis (collagen, fibroblasts, fibrocytes).



a



b



c

9. TABLES

Table 1: Literature review about series involving patients treated with polyglycolic acid/trimethylene carbonate Bio-A biosynthetic, absorbable mesh (*Laparoscopic sleeve gastrectomy; **Hiatal hernia repair; *Laparoscopic re-sleeve gastrectomy; ****Gastric bypass)⁶¹.**

Author, publication's year	N	Type of procedure	Mean BMI (Kg/m2)	Mean F – up (months)	Complications rate (mesh related) (%)	Recurrence (%)
Massullo, 2012	11	Nissen / Toupet fundoplication	30.7	12	0	9
Powell BS, 2013	70	Nissen fundoplication	28.3	n.s. (from few weeks to 18 months)	0	0%
Silecchia, 2014	43	20 primary LSG(A) 13 HHR post LSG(B); 10 Nissen (C)	A= 43.2 B= 33 C= 26.4	17.4	0	2.3
Alicuen, 2014	114	Nissen fundoplication Collins 4 pts.	n	up to 36	0	0.9%
Priego, 2014	10	Nissen fundoplication	31.65	20.3	0	10
Berselli, 2015	8	7 Nissen fundoplication 1 Toupet fundoplication	30.1	24 (14-44)	0	20% asymptomatic radiological
Ruscio 2016 Boru 2019	48	LSG	42.56	60	0	4.1

Cristian Eugeniu Boru

Macedo, 2017	6	HHR after LSG	35.8	20.2	0	0
Asti, 2017	100	Toupet fundoplication	27.2	30	0	9
Paganini, 2017	17	LSG	43.5 ± 4.7	18.1 ± 11.3	0	0
Olson, 018	399	225 Nissen 170 Toupet 4 Dor	Mean BMI 29 A53: BMI < 25; B166: BMI 25-29.9; C 115: BMI 30-34.9; D65: BMI ≥ 35	44.7 ± 22.8	0	7.9%
Iossa 2019	120	60 LSG; 15 re-LSG; 17 GBP; 28 Nissen	43.4 (Group A) 23 (Group B)	41	0	Total series: 5.8 5.4 (Obese) 7.1 (Normal)

Table 2: Clinical card of daily monitoring. Grimace scale⁴⁹

Doctor	N. pig	Data	Grimace scale				
Heart rate		bpm	Temporal tension	0	1	2	
Respiratory rate		resp/min	Forehead profile	0	1	2	
Rectal temp		°C	Orbital tightening	0	1	2	
Mucosa's color	pink	pale	cyanotic	Cheek tension	0	1	2
Capillary filling time	<2 sec	2-3 sec	>3 sec	Tension above eyes	0	1	2
Digestive transit	yes	no	Lower jaw profile	0	1	2	
Diuresis	Yes	no	Upper lip contraction	0	1	2	
Water drinking	Yes	no	Snout plate changes	0	1	2	
Eating	yes	no	Snout angle	0	1	2	
Observations			Nostril dilatation	0	1	2	
			Total score				

Table 3: **Body Condition Scoring**⁵⁰

Score Number	Condition	Description	Shape of body
5	Overfat	Hips and backbone heavily covered	Bulbous
4	Fat	Hips and backbone cannot be felt	Tending to bulge
3.5	Good condition	Hips and backbone only felt with difficulty	Tube shape
3	Normal	Hips and backbone only felt with firm palm pressure	Tube shaped
2.5	Somewhat thin	Hips and backbone felt without palm pressure	Tube shaped but flat (slab) sides
2	Thin	Hips and backbone noticeable and easily felt	Ribs and spine can be felt
1	Emaciated	Hips and backbone visible	Bone structure apparent (ribs and backbone)

Table 4: HP findings in both groups

Group	<i>Proliferative fibroblast-fibrocyte-collagen-neoformation component</i>	<i>Vascular component</i>	<i>Inflammatory component: chronic nodular aspect mainly, with rare acute or sub-acute zones</i>
Bio-A® group	<p>Cellular part (fibroblasts and fibrocytes)</p> <p>Neo-fibril-conjunctively part (collagen PAS + and alcian blue +)</p> <p>Coarse collagen fibers (Blue/ green collagen Trichrome Masson)</p>	<p>- Vascular neo-formation (different calibers)</p> <p>- Intense and wide-spread active hyperemia, both arterioles and veins ± perivascular hepatic extravasation</p> <p>- endothelithis and sclerogenic thrombo-arteriopathy, with multiple fibril-conjunctival proliferations mainly PAS + and alcian blue + rarely.</p>	<p>- Granulocytes, neutrophils and eosinophil</p> <p>- mononuclear cells like lymphocytes, plasmocytes, macrophages and histiocyte</p> <p>- chronic nodular aspect mainly</p>
PRP group	<p>Almost the same as in group A</p>	<p>Only neovascularization phenomenon, with relatively frequent aspects of active hyperemia</p>	<p>Present only in the conjunctive tissue, organized as nodular chronic inflammation, with lymphocytes, plasma cells and macrophages.</p>

Table 5: Semiquantitative HP scoring of tissue reaction, calculated based on:

- inflammation 0 = absent, 1 = mild detectable, 2 = present, 3 = marked/very evident;
- fibrosis (collagen, fibroblast, fibrocytes): 0= absent, 1 slightly detectable, 2 mild, 3 marked;
- vascularization: 0 absent, 1 rare, 2 some (3-5), 3 (over 5 vessels).

Group	Inflammatory response	Vascularization	Fibrosis
Mesh group			
pig 1/	2	2	3
pig 2/ P1	3	3	2
pig 3/ P6	2	3	3
pig 5/ P5	3	1	3
pig 6/	3	2	3
pig 4	3	2	3
Median	3	2	3
Average	2,666666667	2,166666667	2,833333333
St.dev	0,516397779	0,752772653	0,40824829
PRP group			
pig 1/ P1	2	1	2
pig 2/ P 12	3	2	3
pig 3/ P 11	3	2	1
pig 4/ P4	0	3	3
pig 5/	1	1	2
pig 6/	2	1	3
Median	2	1,5	2,5
Average	1,833333333	1,666666667	2,333333333
St.dev	1.169045194	0.816496581	0,16496581
p (Wilcoxon)	0.1908	0.3061	0.2482
p (chi quadro)	0.4459	0.4646	0.3998

10. LIST OF PUBLICATIONS

30/12/2019

Articles in journals

1. **Boru CE**, Angelis F, Iossa A, Antypas P, Ciccioriccio C, Termine P, Silecchia G. Persistent Fistula after Sleeve Gastrectomy: A Chronic Dilemma. **Chirurgia (Bucur)**. 2019 Nov-Dec;114(6):790-797.
2. Boru CE, Rengo M, Iossa A, De Angelis F, Massaro M, Spagnoli A, Guida A, Laghi A, Silecchia G. Hiatal Surface Area CT scan measurement is useful in hiatal hernia's treatment of bariatric patients. **Minim Invasive Ther Allied Technol**. Nov 2019 [Epub ahead of print] doi: 10.1080/13645706.2019.1683033. **Impact factor 1.154**
3. Boru CE, Coluzzi MG, De Angelis F, Silecchia G. Long-Term Results After Laparoscopic Sleeve Gastrectomy with Concomitant Posterior Cruroplasty: 5-Year Follow-up. **J Gastrointest Surg**. 2019 Aug 13. doi: 10.1007/s11605-019-04355-1. [Epub ahead of print] **Impact factor 2.686**
4. Boru CE, Greco F, Giustacchini P, Raffaelli M, Silecchia G. Short-term outcomes of sleeve gastrectomy conversion to R-Y gastric bypass: multi-center retrospective study. **Langenbecks Arch Surg**. 2018; 403(4):473-479. doi: 10.1007/s00423-018-1675-0. **Impact factor 2.093**.
5. Boru CE, Manzia TM, Silecchia G. Pandora's Box: Unpredictable Evolution of a 20-Year History of a Bariatric Patient-Report of Small Bowel Migrated Gastric Band after Redo Banded Gastric Bypass. **Obes Surg**. 2018; 28(5):1422-1424. doi: 10.1007/s11695-018-3159-2. **Impact factor 3.346**.
6. Celik S, Ringe KI, **Boru CE**, Constantinica V, Bektas H. A case of pancreatic cancer with concomitant median arcuate ligament syndrome treated successfully using an allograft arterial transposition. *Journal of Surgical Case Reports*, 2015; 12:1–4.
7. Cavallaro G, Campanile FC, Rizzello M, Greco F, Iorio O, DeAngelis F, Rengo M, **Boru C**, Silecchia G. Laparoscopic incisional hernia repair by light weight polypropylene mesh with resorbable coating. Technical notes, preliminary results. **Chirurgia (Bucuresti)** 2013; 108(3): 304-11.
8. Campanile FC, **Boru CE**, Rizzello M, Puzziello A, Copaescu C, Cavallaro G, Silecchia G. Acute complications after laparoscopic bariatric procedures: update for the general surgeon. **Langenbecks Arch Surg** 2013; 398 (5): 669-86.
9. **Boru EC**, Silecchia G. Bariatric emergencies: what should know the general surgeon. **Chirurgia (Bucuresti)** 2010; 105 (4): 455-464.

10. Marincas M, Bratucu E, Badarau A, Straja D, **Boru EC**, Stefan I, Drilea E. External drainage of the hepatic postthydatid remnant cavity. **Chirurgia** **2009**; 104(2):151-157.
11. **Boru EC**, Bacci V and Silecchia G. Bariatric surgery and cardiovascular system. **Journal of EndoCardiology** **2008**; 1 (2): 97-116. (Nova Science Publishers, Canada).
12. Iordache N, Copaescu C, Litescu M, Munteanu R, **Boru EC**, Stoica A. Bariatric surgery evolution in Romania. Results during first year after a variety of bariatric procedures. **Acta Endocrinologica (Buc)** **2008**; 2 (4): 161-172.
13. Silecchia G, **Boru EC**, Mouiel J, et al. The use of fibrin sealant to prevent major complications following laparoscopic gastric bypass: results of a multicenter, randomized trial. **Surg Endosc** **2008**; 22(11):2492-7.
14. Brătucu E, Straja D, Marincas M, Daha C, Cirimbei C, **Boru EC**. Late choledochal pathology after cholecystectomy for cholelithiasis. **Chirurgia** **2006**;101(3):289-95.
15. Silecchia G, **Boru EC**, J Mouielet al. Clinical evaluation of fibrin glue in the prevention of anastomotic leak and internal hernia after laparoscopic gastric bypass: preliminary results of a prospective, multicenter, randomised trial. **Obes Surg** **2006**; 16: 125-131.
16. Silecchia G, **Boru EC**, Perrotta N et al. Laparoscopic splenectomy in the management of benign and malignant hematologic diseases. **J Soc Laparo Endosc** **2006**; 10(2): 199-205.
17. Silecchia G, **Boru EC** et al. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super obese high-risk patients. **Obes Surg** **2006**; 16 (9): 1138-44.
18. **Boru EC**, Silecchia G, Pecchia A et al. Prevalence of cancer in Italian obese patients referred for bariatric surgery. **Obes Surg** **2005**; **15**: 1171-76.
19. Silecchia G, Greco F, Bacci V, **Boru EC**, Basso N et al. Results after laparoscopic gastric banding in patients over 55 years of age. **Obes Surg** **2005**; **15**: 351-6.
20. Silecchia G, Perrotta N, **Boru EC**, Basso N et al. Role of minimally invasive approach in the management of laparoscopic adjustable gastric banding postoperative complications. **Arch Surg** **2004**; 139 (10): 1225-1230.
21. Bratucu E, Marincas M, **Boru EC**. Particular evolution of a jejunal tumor in one patient with multiple neoplasia. **Chirurgia (Buc.)** **2004**; 1, 99:57-60.
22. Marincas M, Bratucu E, Straja D, Daha C, **Boru EC**. Acute necrotizing enteritis in adults. **Chirurgia (Buc.)** **2003**, 2 (98):143-147.

Articles under revision/publication

1. Rengo M, **Boru CE**, Badia S, Bellini D, Panvini N, Carbone I, Laghi A, Silecchia G. MDCT preoperative analysis of Hiatal Surface Area in patients candidates to hiatoplasty: a valid help in the choice of the treatment of the hiatal defect? Submitted 2019 to **Eur J Radiol Impact Factor 4,014**.
2. **Boru CE**, Manolescu N, Ulmeanu D, Copaescu C, Silecchia C. Evaluation of the histopathological modifications induced by autologous platelet rich plasma vs. biosynthetic absorbable mesh as reinforcement of cruroplasty: a study on an animal study. Submitted to J Surg Res Impact factor 2.187.

Chapters in textbooks

1. **C. Boru**. Sleep disturbances and bariatric surgery. In Tulburarile de somn, sub cond. C. Sarafoleanu. Ed. Academiei Medicale 2016.
2. **C. Boru**, A. Secureanu. Tratatamentul chirurgical al obezitatii morbide (patologice) in Alimentatia si Patologia, sub cond. L. Parvu. Ed. EuroEdit 2012.
3. G Silecchia, **Boru CE**. Biological fibrin glue in laparoscopy. In Frezza E, Gagner M, Li MKW: International Principles of Laparoscopic Surgery. Ed. Cine-Med, New York, 2009.
4. Iordache N, **Boru CE**, Lițescu M, Iorgulescu A, Stoica A. Terapii chirurgicale în obezitatea morbidă. In Peretianu D: Echilibrul energetic și obezitatea. Ed. All, Bucuresti 2009.



Cristian Eugeniu Boru

Pag 80

11. REFERENCES

- ¹ Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as risk factor for esophageal adenocarcinoma. *N Engl J Med* 1999; 340: 825-831.
- ² Kohn GP, Price RR, DeMeester SR, Zehetner J, Muensterer OJ, Awad Z, Mittal SK, Richardson WS, Stefanidis D, Fanelli RD; SAGES Guidelines Committee. Guidelines for the management of hiatal hernia. *Surg Endosc*. 2013; 27(12): 4409-28.
- ³ Frazzoni M, Piccoli M, Conigliaro R, Frazzoni L, Melotti G. Laparoscopic fundoplication for gastroesophageal reflux disease. *World J Gastroenterol*. 2014 21; 20 (39): 14272-9.
- ⁴ Fuchs KH, Babic B, Breithaupt W, Dallemagne B, Fingerhut A, Furnee E, Granderath F, Horvath P, Kardos P, Pointner R, Savarino E, Van Herwaarden-Lindeboom M, Zaninotto G; European Association of Endoscopic Surgery (EAES). EAES recommendations for the management of gastroesophageal reflux disease. *Surg Endosc*. 2014; 28(6): 1753-73.
- ⁵ Page PA, Furtado R, Hayward M, Law S, Tan A, Vivian SJ, Van der Wall H, Falk GL. Durability of giant hiatus hernia repair in 455 patients over 20 years. *Ann R Coll Surg Engl* 2015; 97: 188-93.
- ⁶ Fei L, del Genio G, Rossetti G, Sampaolo S, Moccia F, Trapani V, Cimmino M, del Genio A. Hiatal hernia recurrence: surgical complication or disease? Electron microscope findings of the diaphragmatic pillars. *J Gastrointest Surg*. 2009;13 (3): 459-64.
- ⁷ Frantzides CT, Madan AK, Carlson MA, Stavropoulos GP. A prospective, randomized trial of laparoscopic polytetrafluoroethylene (PTFE) patch repair vs simple cruroplasty for large hiatal hernia. *Arch Surg*. 2002; 137(6): 649-52.
- ⁸ Huddy JR, Markar SR, Ni MZ, Morino M, Targarona EM, Zaninotto G, Hanna GB. Laparoscopic repair of hiatus hernia: Does mesh type influence outcome? A meta-analysis and European survey study. *Surg Endosc*. 2016; 30(12): 5209-5221.
- ⁹ Acin-Gandara D, Miliani-Molina C, Carneros-Martin J, Martinez-Pineiro J, Vega MD, Pereira-Perez F. Transmural gastric migration of dual-sided PTFE/ePTFEE mesh after laparoscopic surgery for a recurrent hiatal hernia with dysphagia: case report. *Chirurgia (Bucur)*. 2014; 109(4): 538-41.
- ¹⁰ Boru CE, Rengo M, Iossa A, De Angelis F, Massaro M, Spagnoli A, Guida A, Laghi A, Silecchia G. Hiatal Surface Area CT scan measurement is useful in hiatal hernia's treatment of bariatric patients. *Minim Invasive Ther Allied Technol*. 2019 [Epub ahead of print]. doi: 10.1080/13645706.2019.1683033.

- ¹¹ Granderath FA, Schweiger UM, Pointner R. Laparoscopic antireflux surgery: tailoring the hiatal closure to the size of hiatal surface area. *Surg Endosc.* 2007; 21(4):542-8.
- ¹² Oelschlager BK, Petersen R, Brunt LM et al. Laparoscopic Paraesophageal Hernia Repair: Defining Long-Term Clinical and Anatomic Outcomes. *J Gastrointest Surg.* 2012; 16: 453–459.
- ¹³ Wang B, Zhang W, Shan CX, Liu S, Jiang ZG, Qiu M. Long-term outcomes of cruroplasty reinforcement with composite versus biologic mesh for gastroesophageal reflux disease. *Surg Endosc.* 2016; 30(7): 2865-72.
- ¹⁴ Biological Mesh: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines – An Update [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2015 Aug 11. Available from <http://www.ncbi.nlm.nih.gov/books/NBK315863>.
- ¹⁵ Petersen LF, McChesney SL, Daly S, Millikan, KW Myers JA, Luu MB. Permanent mesh results in long-term symptom improvement and patient satisfaction without increasing adverse outcomes in hiatal hernia repair. *Am J Surg.* 2014; 207(3): 445-8; discussion 448.
- ¹⁶ Zhang W, Tang W, Shan CX, Liu S, Jiang ZG, Jiang DZ, Zheng XM, Qiu M. Dual-sided composite mesh repair of hiatal hernia: our experience and a review of the Chinese literature. *World J Gastroenterol.* 2013; 19 (33): 5528-33.
- ¹⁷ Parker M, Bowers SP, Bray JM, Harris AS, Belli EV, Pfluke JM, Preissler S, Asbun HJ, Smith CD. Hiatal mesh is associated with major resection at revisional operation. *Surg Endosc.* 2010; 24 (12): 3095-101.
- ¹⁸ Priego P, Perez de Oteyza J, Galindo J, Carda P, García-Moreno F, Rodríguez Velasco G, Lobo E. Long-term results and complications related to Crurasoft® mesh repair for paraesophageal hiatal hernias. *Hernia.* 2017; 21(2):291-298.
- ¹⁹ Granderath FA, Schweiger UM, Kamolz T, Asche KU, Pointner R. Laparoscopic Nissen fundoplication with prosthetic hiatal closure reduces postoperative intrathoracic wrap herniation: preliminary results of a prospective randomized functional and clinical study. *Arch Surg.* 2005; 140: 40–48.
- ²⁰ Boru CE, Coluzzi MG, de Angelis F, Silecchia G. Long-term Results after laparoscopic sleeve Gastrectomy with concomitant posterior cruroplasty: 5-Year Follow-up. *J Gastrointest Surg.* 2019 Aug 13. doi: 10.1007/s11605-019-04355-1.
- ²¹ Deeken CR, Matthews Bd. Characterization of the mechanical strength, resorption properties and histologic characteristics of a fully absorbable material (Poly-hydroxybutyrate- Phasix Mesh) in a porcine model of hernia repair. *ISRN Surg.* 2013: 238067. doi: 10.1155/2013/238067.
- ²² Miserez M, Jairam AP, Boersema GSA, Bayon Y, Jeekel J, Lange JF. Resorbable Biosynthetic Meshes for Abdominal Wall Defects in Preclinical Setting: A Literature Review. *J Surg Res.* 2019; 237: 67-75.
- ²³<https://www.goremedical.com/eu/products/bioatissuespecifications>.

- ²⁴ Elango S, Perumalsamy S, Ramachandran K, Vadodaria K. Mesh materials and hernia repair. *Biomedicine (Taipei)*. 2017; 7(3):16. doi: 10.1051/bmdcn/2017070316.
- ²⁵ Fernandez-Moure Js, Van Eps JL, Cabrera FJ, Barbarosa Z, del Rosal GM, Weiner BK, Ellsworth WA, Tasciotti E. Platelet-rich plasma: a biomimetic approach to enhancement of surgical wound healing. *J Surg Res* 2017; 207: 33-44.
- ²⁶ Marques LF, Stessuk T, Camargo IC, Sabeh Junior N, Dos Santos L, Ribeiro-Paes JT. Platelet-rich plasma (PRP): methodological aspects and clinical applications. *Platelets*. 2015; 26 (2): 101-113.
- ²⁷ Mazzucco L, Borzini P, Gope R. Platelet-Derived Factors Involved in Tissue Repair—From Signal to Function. *Transfus Med Rev*. 2010; 24(3):218-234.
- ²⁸ Anitua E, Alkhraisat MH, Orive G. Perspectives and challenges in regenerative medicine using plasma rich in growth factors. *J Control Release*. 2012; 157(1):29-38.
- ²⁹ Decreto Ministero della Salute 3 marzo 2005. Caratteristiche e modalità per la donazione del sangue e di emocomponenti. *Gazzetta Ufficiale* n. 85 del 13 aprile 2005.
- ³⁰ Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and treatment of chronic nonhealing wounds. Successful treatment with autologous platelet-derived wound healing factors (PDWHF). *Ann Surg*. 1986; 204(3): 322-330.
- ³¹ Steed DL, Goslen JB, Holloway GA, Malone JM, Blunt TJ, Webster MW. Randomized prospective double-blind trial in healing chronic diabetic foot ulcers. CT-102 activated platelet supernatant, topical versus placebo. *Diabetes Care*. 1992; 15(11): 1598-1604.
- ³² Marx RE, Carlson ER, Eichstaedt RM, Schimmele SR, Strauss JE, Georgeff KR. Platelet-rich plasma: growth factor enhancement for bone grafts. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 1998; 85(6): 638-646.
- ³³ Crovetto G, Martinelli G, Issi M, et al. Platelet gel for healing cutaneous chronic wounds. *Transfus Apher Sci*. 2004; 30(2): 145-151.
- ³⁴ Mazzucco L, Medici D, Serra M, et al. The use of autologous platelet gel to treat difficult-to-heal wounds: a pilot study. *Transfusion*. 2004; 44(7): 1013-1018.
- ³⁵ Borzini P, Mazzucco L. Tissue regeneration and in loco administration of platelet derivatives: clinical outcome, heterogeneous products, and heterogeneity of the effector mechanisms. *Transfusion*. 2005; 45(11): 1759-1767.
- ³⁶ O'Connell SM, Impeduglia T, Hessler K, Wang XJ, Carrol RJ, Dardik H. Autologous platelet-rich fibrin matrix as cell therapy in the healing of chronic lower-extremity ulcers. *Wound Repair Regen*. 2008; 16 (6): 749-756.
- ³⁷ Mei-Dan O, Carmont MR. Novel Applications of Platelet-Rich Plasma Technology in Musculoskeletal Medicine and Surgery. *Oper Tech Orthop*. 2012; 22: 56-63.

³⁸ Tambella AM, Attili AR, Dini F, Palumbo Piccionello A, Vullo C, Serri E, Scrollavezza P, Dupré G. Autologous Platelet Gel to Treat Chronic Decubital Ulcers: A Randomized, Blind Controlled Clinical Trial in Dogs. *Vet Surg.* 2014; 43(6): 726-733.

³⁹ Sakata R, Reddi AH. Platelet-rich plasma modulates actions on articular cartilage lubrication and regeneration. *Tissue Eng Part B Rev.* 2016; 22(5):408-419.

⁴⁰ Mazzucco L, Balbo V, Guaschino R. “Reasonable compromise” to define the quality standards of platelet concentrate for non-transfusion use (CPunT). *Transfus Apher Sci.* 2012; 47(2): 207-211.

⁴¹ Franz MG, Kuhn MA, Nguyen K et al. Transforming growth factor b(2) lowers the incidence of incisional hernias. *J Surg Res* 2001; 97(2): 109–116.

⁴² Dubay DA, Wang X, Kuhn MA, Robson MC, Franz MG. The prevention of incisional hernia formation using a delayed-release polymer of basic fibroblast growth factor. *Ann Surg* 2004; 240(1): 179–186.

⁴³ Van Eps J, Fernandez-Moure J, Cabrera F, Wang X, Karim A, Corradetti B, Chan P, Dunkin B, Tasciotti E, Weiner B, Ellsworth W 4th. Decreased hernia recurrence using autologous platelet-rich plasma (PRP) with Stratice™ mesh in a rodent ventral hernia model. *Surg Endosc.* 2016; 30 (8): 3239-49.

⁴⁴ Altieri MS, Pagnotti G, Corthals A, Shroyer K, Pryor AD, Talamini M, Telem DA. Autologous augmentation of hiatal hernia repair with filtered platelet concentrate improves tissue remodeling in a swine model. *Surg Endosc* 2017; 31(4): 1591-1598.

⁴⁵ M. Michael Swindle, Alison C. Smith & Bradley J. S. Hepburn. Swine as Models in Experimental Surgery, *Journal of Investigative Surgery* 2009; 1:1,65-79.

⁴⁶ Asti E, Lovece A, Bonavina L, Milito P, Sironi A, Bonitta G, Siboni S. Laparoscopic management of large hiatus hernia: five-year cohort study and comparison of mesh-augmented versus standard crura repair. *Surg Endosc* 2016; 30(12): 5404-5409.

⁴⁷ Scott JR, Deeken CR, Martindale RG, Rosen MJ. Evaluation of a fully absorbable poly-4-hydroxy-butyrates/absorbable barrier composite mesh in a porcine model of ventral hernia repair. *Surg Endosc.* 2016; 30(9):3691-701.

⁴⁸ <https://www.asahq.org/resources/clinical-information/asa-physical-status-classification-system>

⁴⁹ Di Giminiani P, Brierley VL, Scollo A, Gottardo F, Malcolm EM, Edwards SA, Leach MC. The Assessment of Facial Expressions in Piglets Undergoing Tail Docking and Castration: Toward the Development of the Piglet Grimace Scale. *Front Vet Sci.* 2016 Nov 14; 3:100.

⁵⁰ Doyle RE, Groat J, Wynn PC, Holyoake PK. Physiological and nonphysiological indicators of body condition score in weaner pigs. *J Anim Sci.* 2015 Apr;93(4):1887-95.

⁵¹ AVMA Guidelines for the Euthanasia of Animals: 2013 Edition. <https://www.avma.org/KB/Policies/Documents/euthanasia.pdf> Am J Veterinary. Accessed 19/09/17.

⁵² Azadani A, Jonsson H, Park PO, Bergström M. A randomized trial comparing rates of abdominal contamination and postoperative infection among natural orifice transluminal endoscopic surgery, laparoscopic surgery, and open surgery in pigs. *Gastrointest Endosc.* 2012; 75(4): 849-55.

⁵³ von Diemen V, Trindade EN, Trindade MR. Hiatal hernia and gastroesophageal reflux: Study of collagen in the phrenoesophageal ligament. *Surg Endosc.* 2016; 30(11): 5091-5098.

⁵⁴ Li J, Cheng T. Mesh erosion after hiatal hernia repair: the tip of the iceberg? *Hernia.* 2019 Jul 23. doi: 10.1007/s10029-019-02011-w. [Epub ahead of print] PubMed PMID: 31338721.

⁵⁵ Koetje JH, Oor JE, Roks DJ, Van Westreenen HL, Hazebroek EJ, Nieuwenhuijs VB. Equal patient satisfaction, quality of life and objective recurrence rate after laparoscopic hiatal hernia repair with and without mesh. *Surg Endosc.* 2017; 31(9):3673-3680.

⁵⁶ Sathasivam R, Bussa G, Viswanath Y, Obuobi RB, Gill T, Reddy A, Shanmugam V, Gilliam A, Thambi P. 'Mesh hiatal hernioplasty' versus 'suture cruroplasty' in laparoscopic para-oesophageal hernia surgery; a systematic review and meta-analysis. *Asian J Surg.* 2019; 42(1):53-60.

⁵⁷ Abouelnasr K, Hamed M, Lashen S, El-Adl M, Eltaysh R, Tagawa M. Enhancement of abdominal wall defect repair using allogenic platelet-rich plasma with commercial polyester/cotton fabric (Damour) in a canine model. *J Vet Med Sci.* 2017; 79(7): 1301-1309.

⁵⁸ Fernandez-Moure JS, Van Eps JL, Menn ZK, Cabrera FJ, Tasciotti E, Weiner BK, Ellsworth WA 4th. Platelet rich plasma enhances tissue incorporation of biologic mesh. *J Surg Res.* 2015; 199(2): 412-9.

⁵⁹ Parizzi NG, Rubini OÁ, Almeida SHM, Ireno LC, Tashiro RM, Carvalho VHT. Effect of platelet-rich plasma on polypropylene meshes implanted in the rabbit vagina: histological analysis. *Int Braz J Urol.* 2017; 43(4): 746-752.

⁶⁰ Hrubnik VV, Iliashenko VV, Hrubnik VV, Paraniak MR. Ways to improve the results of laparoscopic antireflux operations in patients with big hiatal hernias. **Medicini perspektivi (Medical perspectives)** 2019 [S.l.] 23; 4: 51-58.

⁶¹ Iossa A, Silecchia G. Mid-term safety profile evaluation of Bio-A absorbable biosynthetic mesh as cruroplasty reinforcement. *Surg Endosc.* 2019; 33(11):3783-3789.